Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Asset Writedowns and Impairment (2018 - 2020)

Historic Asset Writedowns and Impairment for Outlook Therapeutics (OTLK) over the last 3 years, with Q2 2020 value amounting to $104296.0.

  • Outlook Therapeutics' Asset Writedowns and Impairment rose 10479.51% to $104296.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $8.9 million, marking a year-over-year change of. This contributed to the annual value of $527624.0 for FY2020, which is 9533.08% down from last year.
  • Latest data reveals that Outlook Therapeutics reported Asset Writedowns and Impairment of $104296.0 as of Q2 2020, which was up 10479.51% from $423328.0 recorded in Q1 2020.
  • Outlook Therapeutics' 5-year Asset Writedowns and Impairment high stood at $8.3 million for Q3 2019, and its period low was $50927.0 during Q2 2019.
  • Its 3-year average for Asset Writedowns and Impairment is $2.0 million, with a median of $492531.5 in 2019.
  • Examining YoY changes over the last 5 years, Outlook Therapeutics' Asset Writedowns and Impairment showed a top increase of 10479.51% in 2020 and a maximum decrease of 2463.92% in 2020.
  • Outlook Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $2.3 million in 2018, then skyrocketed by 254.9% to $8.3 million in 2019, then tumbled by 98.75% to $104296.0 in 2020.
  • Its last three reported values are $104296.0 in Q2 2020, $423328.0 for Q1 2020, and $8.3 million during Q3 2019.